Interreg Italia-Slovenija

IMMUNOCLUSTER-2

Cofinanziato dall'Unione europea
Sofinancira Evropska unija

IMMUNOCLUSTER-2

Cross-border cooperation for advanced breast cancer therapy



Initiation of a clinical trial of a cell-based advanced therapy medicinal product (ATMP) - autologous immunohybridoma cells (aHyC) - for the treatment of triple-negative breast cancer (TNBC), enabling access to advanced, personalized therapies.

Partners	ERDF	01.09.2023
6	592.047,68	31.12.2025

www.ita-slo.eu/immunocluster-2

PARTNERS

celica biomedical

Onkološki Inštitut
Institute of Oncology
Ljubljana

VivaBioCell

UNIVERSITÀ
DEGLI STUDI
DI UDINE

ASU FC
Azienda sanitaria
universitaria
Friuli Centrale

Zavod Republike Slovenije
za transfuzijsko medicino
Slovenian Institute for Transfusion Medicine

Project goals

- Launch a clinical trial of the aHyC medicinal product for patients with TNBC.
- Develop and enhance innovation capacities and introduce advanced technologies into practice.
- Transfer knowledge from the previously completed IMMUNO-CLUSTER projcet.

Innovative technologies

- Manufacturing process for the preparation of the innovative aHyC cell-based medicinal product.
- The NANT XL Plus bioreactor enables increased production of the aHyC cell-based medicine.
- Integration of innovative technologies into the manufacturing process.
- Automated production and validation in accordance with Good Manufacturing Practice (GMP) standards.





Project achievements

- Preparation and optimization of requirements and protocols for the collection of leukapheresis products and for the production of dendritic cells and immunohybridoma cells for TNBC.
- Synchronization of procedures and validation of cell-based medicine production in a GMP environment using NANT XL Plus technology.





- Identification and harmonization of regulatory requirements and ethical approvals on both sides of the border.
- Identification of suitable public and private hospitals and TNBC patients.
- Improved access for TNBC patients to additional advanced treatment with aHyC.
- Possibility for patients from Italy to participate in the clinical study with treatment provided in Slovenia.

Final Immunocluster-2 event

Friday, December 05, 2025
at the Institute of Oncology, Ljubljana

Next steps

- Start of aHyC cell-based medicine production according to GMP standards.
- Increase access to advanced therapy for TNBC patients.
- Expand innovation and transfer technologies to small and medium-sized enterprises in the region.
- Strengthen cooperation among research, healthcare and business partners.

KEY MESSAGE

The project opens the possibility for patients with triple-negative breast cancer on both sides of the border to receive **advanced**, **safe** and **accessible** treatment.

The IMMUNOCLASTER-2 project is co-financed by the European Union within the Interreg VI-A Italy-Slovenia Program.